Biosyntia, a Copenhagen, Denmark-based industrial biotech company, raised €11.5M in funding.
The round was closed with an investment from the European Circular Bioeconomy Fund (ECBF) and the two existing investors, Sofinnova Partners and Novo Seeds, the early-stage investment and company creation team of Novo Holdings A/S.
The company intends to use the funds to enter the production phase of its natural and sustainable active ingredients as well as expand the pipeline of products.
Led by CEO Martin Plambech, Biosyntia is an industrial biotech company that develops bio-based manufacturing processes with all critical capabilities for success inhouse – stretching from microbial engineering, fermentation optimization, product purification, formulation to sales. Biosyntia focuses especially at developing more natural and sustainable processes for active ingredients used in beauty and nutrition such as vitamins, antioxidants and similar ingredients. The company has developed proprietary technologies such as Biosynthetic Selections, which reduce the risk, cost and time for developing fermentation processes.
The first product to be commercialized is a bio-based biotin (vitamin B7), for use in dietary supplements, food, and beauty products.
Biosyntia, which has several commercial partnerships, including collaborations with large market players such as Givaudan and WACKER, has 20 scientists and business developers, which operates from its lab and offices in Copenhagen, Denmark.
FinSMEs
07/07/2022